The Brain Imaging Data Structure (BIDS) is a standard specifying the description of neuroimaging data in a filesystem hierarchy and of the metadata associated with the imaging data. Membership on the BIDS Steering Group is through elections by BIDS Contributors, and BIDS Steering Group terms are 3 years. The goal of BIDS is to make neuroimaging data more accessible, shareable, and usable by researchers. To achieve this goal, BIDS seeks to develop a simple and intuitive way to organize and describe neuroimaging and associated data. BIDS has three foundational principles:
To minimize complexity and facilitate adoption, reuse existing methods and technologies whenever possible.
Tackle 80% of the most commonly used neuroimaging data, derivatives, and models (inspired by the pareto principle).
Adoption by the global neuroimaging community and their input during the creation of the specification is critical for the success of the project.
Congratulations to Louise Møller Jørgensen who has been appointed Clinical Associate Professor withfunction as innovation ambassador at Department of Clinical Medicine, University of Copenhagen. Louise will begin in this new function November 1 and will be serving in SUND’s Innovation working group, which aim to advance innovations and entrepreneurship set off in the clinics.
Congratulations to NRU post doc Dea Siggaard Stenbæk for receiving an International Postdoc grant worth 1.575.000 DKK from Independent Research Fund Denmark for the project entitled 'Brain dynamics of psychedelic serotonin 2A stimulation and music'.
Project period: 01-01-2020 to 31-12-2021.
Brief scentific summary of project: Serotonin 2A receptor stimulation with the psychedelic compound psilocybin is emerging as a promising treatment for affective disorders, which includes the use of music as support. Music evokes a wide range of emotions and can change the way we think and feel about ourselves. However, a better understanding of the neurobiological mechanisms by which music interplay with psychoactive effects of psilocybin is needed to inform us about its clinical utility. I propose to evaluate changes in brain connectivity in response to psilocybin and music measured with functional magnetic resonance imaging, and to correlate such changes with cerebral serotonin 2A receptor binding measured with positron emission tomography. International partners are leading world experts from the Psychedelic Research Group at Imperial College London where I plan to stay for 12 months. Results from the study will contribute significantly to our understanding of the role played by music in psilocybin-assisted therapy.